Genflow Biosciences PLC GENFF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.03
- Day Range
- $0.05–0.05
- 52-Week Range
- $0.01–0.07
- Bid/Ask
- $0.00 / $0.05
- Shares Outstanding
- 594.53M
- Market Cap
- $24.10M
- Volume/Avg
- 700 / 33,968
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Genflow Biosciences PLC is a preclinical biotechnology company focused on the development of biological interventions (namely gene therapies) which are aimed at tackling the effects of aging, potentially slowing or halting the aging process and so reducing the incidence of age-related diseases and thereby increasing health span. Its flagship compound, GF-1002, is based on the delivery of a variant of the SIRT6 gene and is currently in preclinical development.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 5
- Website
- https://www.genflowbio.com
Valuation
|
Metric
|
GENFF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 101.36 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
GENFF
|
|---|---|
Quick Ratio | 1.28 |
Current Ratio | 1.34 |
Interest Coverage | −2,177.57 |
Quick Ratio
GENFF
Profitability
|
Metric
|
GENFF
|
|---|---|
Return on Assets (Normalized) | −197.64% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
GENFF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|LJ#Q#%% | LOCK|Xt#& | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|HFyh@>^ | LOCK|S#%Gf | $83B | |||
| Moderna Inc
MRNA
| LOCK|#ncTSZk | LOCK|Jt& | $80B | |||
| argenx SE ADR
ARGX
| LOCK|X?LJv@M | LOCK|NT | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%^$DNB | LOCK|VT# | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|D!Bsqfz | LOCK|yfD$H | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|^^%bMS^L | LOCK|kMWK | $28B | |||
| Incyte Corp
INCY
| LOCK|>WH!FX& | LOCK|WRZ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|h$XT>B< | LOCK|M% | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|cYY##j@ | LOCK|R< | $14B |
United States